Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shionogi To Buy U.S. Specialty Drug Maker Victory Pharma

This article was originally published in PharmAsia News

Executive Summary

Shionogi's U.S. unit Sciele Pharma announced a plan to pay $150 million to acquire Victory Pharma, a U.S. pharmaceutical company specializing in pain drugs. The deal is expected to complete next month. The addition of Victory will further strengthen Shionogi's presence in the pain market, which has been one of the target therapeutic areas for the company. Shionogi also plans to introduce new products through Sciele. (Click here for more - Japanese language

You may also be interested in...



Novartis And The Medicines Company: Five Things To Worry About

The $9.7bn acquisition hinges on the small interfering RNA inclisiran, but an ongoing cardiovascular outcomes trial, manufacturing hurdles, and reimbursement challenges provide subjects for concern.

QUOTED. 12 December 2019. Scott Whitaker

US congressional leaders and medtech industry advocacy group AdvaMed are giving their full-throated endorsement to a US-Mexico-Canada (USMCA) trade agreement announced by the US Trade Representative's Office on 10 December. See what AdvaMed's president and CEO, Scott Whitaker, said about it in a statement here.

Horizon Teprotumumab's US Advisory Cmte. Likely To Focus On Labeling, Not Approval, Questions

FDA seems poised to approve the drug for the orphan eye disease called TED, but remains concerned about labeling for some adverse events.

UsernamePublicRestriction

Register

SC071698

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel